Myeloid Progenitor Inhibitory Factor 1 (MPIF-1)

Myeloid Progenitor Inhibitory Factor 1 (MPIF-1; CCL23) is a highly basic protein, highly chemotactic for resting T-cells and monocytes and slightly chemotactic for neutrophils. It is found predominately in lung and liver tissue but also found in bone marrow and placenta. It has been found to inhibit activity of hematopoietic progenitor cells. High levels in adult lung, liver, skeletal muscle, and pancreas. Moderate levels are found in fetal liver, adult bone marrow, and placenta. The short form is the major species and the longer form was detected only in very low abundance. CCL23(19-99), CCL23(22-99), CCL23(27-99), CCL23(30-99) are found in high levels in synovial fluids from rheumatoid patients.

Swiss-Prot Accession Number: P55773


Myriad RBM Publications Publications
Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-na?ve schizophrenia (2022) Santiago G. Lago, Jakub Tomasik, Geertje F. Rees, Nitin Rustogi, Javier Vazquez-Bourgon, Sergi Papiol, Paula Suarez-Pinilla, Benedicto Crespo-Facorro, Sabine Bahn Brain Behavior and Immunity
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy (2021) Choueiri TK, Atkins MB, Rose TL, Alter RS, Yawen J, Niland K, Wang Y, Arbeit R, Parasuraman S, Gan L, McDermott DF Investigational New Drugs
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment (2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One
Circulating Biomarkers and Outcome from a Randomised Phase Ii Trial of Sunitinib Vs Everolimus for Patients with Metastatic Renal Cell Carcinoma (2016) Voss MH, Chen D, Marker M, Hakimi AA, Lee C-H, Hsieh JJ, Knox JJ, Voi M, Motzer RJ British Journal of Cancer
Variation in Serum Biomarkers with Sex and Female Hormonal Status: Implications for Clinical Tests (2016) Ramsey JM, Cooper JD, Penninx BWJH, Bahn S Scientific Reports
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli. (2016) S?derlund S, Christiansson L, Persson I, Hjorth-Hansen H, Richter J, Simonsson B, Mustjoki S, Olsson-Str?mberg U, Loskog A. Leuk Res